Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors
Status:
Terminated
Trial end date:
2020-02-17
Target enrollment:
Participant gender:
Summary
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability,
pharmacodynamics and efficacy of birinapant when given in combination with pembrolizumab. A
dose expansion phase of 4 cohorts will also be included.